Ask AI
ProCE Banner Activity

ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Slideset Download

Download this slideset to review the latest data on new directions using antibody drug conjugates in HER2-positive breast cancer and beyond.

Released: October 30, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

International Breast Cancer Center (IBCC), Pangea Oncology, Quiron Group
Barcelona, Spain
IOB Madrid, Institute of Oncology
Hospital Beata María Ana
Madrid, Spain

Javier Cortes, MD, PhD: consultant/advisor: AbbVie, AstraZeneca, Bioasis, BioInvent, Biocon, BioNtech, Bliss, Boehringer Ingelheim, BridgeBio, Circle, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion, Gemoab, Gilead, Hexagon Bio, HiberCell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Relay, Reveal Genomics, Roche, Scorpion, Seattle Genetics, Zymeworks; researcher (paid to institution): Aria, AstraZeneca, Bayer Healthcare, Baxalta GmbH/Servier Affaires, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqure, Roche; other material or financial support: AstraZeneca, Daiichi Sankyo, Esiai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; royalties or patent beneficiary: issued patent: pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent (WO 2014/199294 A), licensed patent: HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy (US 2019/0338368 A1); stock: Leuko.